MRNA-Based Therapeutics in Cancer Treatment

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2023 Feb 25

PMID 36839944

Authors

Han Sun

Yu Zhang

Ge Wang

Wen Yang

Yingjie Xu

Affiliations

Soon will be listed here.

Abstract

Over the past two decades, significant technological innovations have led to messenger RNA (mRNA) becoming a promising option for developing prophylactic and therapeutic vaccines, protein replacement therapies, and genome engineering. The success of the two COVID-19 mRNA vaccines has sparked new enthusiasm for other medical applications, particularly in cancer treatment. In vitro-transcribed (IVT) mRNAs are structurally designed to resemble naturally occurring mature mRNA. Delivery of IVT mRNA via delivery platforms such as lipid nanoparticles allows host cells to produce many copies of encoded proteins, which can serve as antigens to stimulate immune responses or as additional beneficial proteins for supplements. mRNA-based cancer therapeutics include mRNA cancer vaccines, mRNA encoding cytokines, chimeric antigen receptors, tumor suppressors, and other combination therapies. To better understand the current development and research status of mRNA therapies for cancer treatment, this review focused on the molecular design, delivery systems, and clinical indications of mRNA therapies in cancer.

Citing Articles

Recent advances in the bench-to-bedside translation of cancer nanomedicines.

Liu Y, Zhang Y, Li H, Hu T Acta Pharm Sin B. 2025; 15(1):97-122.

PMID: 40041906 PMC: 11873642. DOI: 10.1016/j.apsb.2024.12.007.

Present and future of cancer nano-immunotherapy: opportunities, obstacles and challenges.

Wang M, Yu F, Zhang Y Mol Cancer. 2025; 24(1):26.

PMID: 39827147 PMC: 11748575. DOI: 10.1186/s12943-024-02214-5.

mRNA vaccines in the context of cancer treatment: from concept to application.

Fu Q, Zhao X, Hu J, Jiao Y, Yan Y, Pan X J Transl Med. 2025; 23(1):12.

PMID: 39762875 PMC: 11702060. DOI: 10.1186/s12967-024-06033-6.

Developer and Partnership Differences in COVID-19 and Other Infections: Insights from DNA Vaccines.

Okuyama R J Mark Access Health Policy. 2024; 12(4):317-325.

PMID: 39588277 PMC: 11587068. DOI: 10.3390/jmahp12040025.

Toward a large-batch manufacturing process for silicon-stabilized lipid nanoparticles: A highly customizable RNA delivery platform.

Saffie-Siebert S, Torabi-Pour N, Gibson A, Sutera F, Dehsorkhi A, Baran-Rachwalska P Mol Ther Methods Clin Dev. 2024; 32(3):101299.

PMID: 39239259 PMC: 11374960. DOI: 10.1016/j.omtm.2024.101299.

References

Henderson J, Ujita A, Hill E, Yousif-Rosales S, Smith C, Ko N . Cap 1 Messenger RNA Synthesis with Co-transcriptional CleanCap Analog by In Vitro Transcription. Curr Protoc. 2021; 1(2):e39. DOI: 10.1002/cpz1.39. View

Do A, Amano T, Edwards L, Zhang L, de Peralta-Venturina M, Yu J . CD133 mRNA-Loaded Dendritic Cell Vaccination Abrogates Glioma Stem Cell Propagation in Humanized Glioblastoma Mouse Model. Mol Ther Oncolytics. 2020; 18:295-303. PMC: 7378271. DOI: 10.1016/j.omto.2020.06.019. View

Sahin U, Oehm P, Derhovanessian E, Jabulowsky R, Vormehr M, Gold M . An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma. Nature. 2020; 585(7823):107-112. DOI: 10.1038/s41586-020-2537-9. View

Vlasova I, Bohjanen P . Posttranscriptional regulation of gene networks by GU-rich elements and CELF proteins. RNA Biol. 2008; 5(4):201-7. PMC: 2642890. DOI: 10.4161/rna.7056. View

Ramaswamy S, Tonnu N, Tachikawa K, Limphong P, Vega J, Karmali P . Systemic delivery of factor IX messenger RNA for protein replacement therapy. Proc Natl Acad Sci U S A. 2017; 114(10):E1941-E1950. PMC: 5347596. DOI: 10.1073/pnas.1619653114. View

Vizcaino J, Csordas A, Del-Toro N, Dianes J, Griss J, Lavidas I . 2016 update of the PRIDE database and its related tools. Nucleic Acids Res. 2015; 44(D1):D447-56. PMC: 4702828. DOI: 10.1093/nar/gkv1145. View

Jansen Y, Kruse V, Corthals J, Schats K, Van Dam P, Seremet T . A randomized controlled phase II clinical trial on mRNA electroporated autologous monocyte-derived dendritic cells (TriMixDC-MEL) as adjuvant treatment for stage III/IV melanoma patients who are disease-free following the resection of macrometastases. Cancer Immunol Immunother. 2020; 69(12):2589-2598. PMC: 11027452. DOI: 10.1007/s00262-020-02618-4. View

Li S, Hu Y, Li A, Lin J, Hsieh K, Schneiderman Z . Payload distribution and capacity of mRNA lipid nanoparticles. Nat Commun. 2022; 13(1):5561. PMC: 9508184. DOI: 10.1038/s41467-022-33157-4. View

Uzri D, Gehrke L . Nucleotide sequences and modifications that determine RIG-I/RNA binding and signaling activities. J Virol. 2009; 83(9):4174-84. PMC: 2668486. DOI: 10.1128/JVI.02449-08. View

10.

Stone J, Chervin A, Kranz D . T-cell receptor binding affinities and kinetics: impact on T-cell activity and specificity. Immunology. 2009; 126(2):165-76. PMC: 2632691. DOI: 10.1111/j.1365-2567.2008.03015.x. View

11.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

12.

van Rosmalen M, Krom M, Merkx M . Tuning the Flexibility of Glycine-Serine Linkers To Allow Rational Design of Multidomain Proteins. Biochemistry. 2017; 56(50):6565-6574. PMC: 6150656. DOI: 10.1021/acs.biochem.7b00902. View

13.

Lichtenegger F, Schnorfeil F, Rothe M, Deiser K, Altmann T, Bucklein V . Toll-like receptor 7/8-matured RNA-transduced dendritic cells as post-remission therapy in acute myeloid leukaemia: results of a phase I trial. Clin Transl Immunology. 2020; 9(3):e1117. PMC: 7053229. DOI: 10.1002/cti2.1117. View

14.

Simon P, Omokoko T, Breitkreuz A, Hebich L, Kreiter S, Attig S . Functional TCR retrieval from single antigen-specific human T cells reveals multiple novel epitopes. Cancer Immunol Res. 2014; 2(12):1230-44. DOI: 10.1158/2326-6066.CIR-14-0108. View

15.

Hoerr I, Obst R, Rammensee H, Jung G . In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies. Eur J Immunol. 1999; 30(1):1-7. DOI: 10.1002/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-#. View

16.

Hu Z, Ott P, Wu C . Towards personalized, tumour-specific, therapeutic vaccines for cancer. Nat Rev Immunol. 2017; 18(3):168-182. PMC: 6508552. DOI: 10.1038/nri.2017.131. View

17.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

18.

Sobczak K, Krzyzosiak W . Structural determinants of BRCA1 translational regulation. J Biol Chem. 2002; 277(19):17349-58. DOI: 10.1074/jbc.M109162200. View

19.

Baas P, Scherpereel A, Nowak A, Fujimoto N, Peters S, Tsao A . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272):375-386. DOI: 10.1016/S0140-6736(20)32714-8. View

20.

Antonia S, Villegas A, Daniel D, Vicente D, Murakami S, Hui R . Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(20):1919-1929. DOI: 10.1056/NEJMoa1709937. View